



## EQUITY RESEARCH

**PAT**  
NEWS  
Press release

**BUY**  
**TP 24.6€**  
Up/Downside: 97%

## Research Collaboration in the Field of Nutraceuticals

The executives announced their first major collaboration agreement in the nutraceutical segment, with a recognised innovation player, Fytexia, which has the support of its new shareholder since 2022: ABF Ingredients division of Associated British Foods.

Management announced the signing of a collaboration agreement with Fytexia in the field of polyphenols, organic molecules present in plants, known for their natural antioxidant roles, with possible applications in human health (pharma, nutraceuticals) and cosmetics.

This agreement is part of the research programme conducted by the company and its subsidiary Cellengo (created in 2019) within the N'GINS consortium, launched in early 2022 (Nouvelle Génération d'Ingrédients Natures Santé), which aims to produce, through metabolic engineering technologies with low environmental impact, new health ingredients, such as new classes of polyphenols, which could supply the dietary supplements market. The project has received the support of public authorities with a funding envelope of €4.8m within the framework of the France 2030 programme in the category "Tomorrow's food needs," including €1.6m for PAT and Cellengo.

In this field of nutraceuticals, management had announced its intention to establish partnerships, co-development and / or industrial partnerships. Thus, this agreement falls in line with the stated strategy. Founded in 2003 in the south of France, Fytexia develops and manufactures high value-added ingredients in the fields of metabolism, nutrition and quality of life. The company is present in Europe, the United States and Asia. Since February 2022, Fytexia has been part of the ABF Ingredients group, a division of Associated British Foods, a UK listed company (€17bn market capitalisation, €20bn in revenue) active mainly in the sourcing, production and distribution of ingredients and derivatives for the food industry.

The track record and the strength of this new partner bodes well for the company's prospects in the nutraceutical sector. To date, the group has one product under development in this sector, in the field of memory protection.

Developments in new segments such as nutraceuticals, health and agrochemicals are continuing, and could, in a few years' time, provide growth drivers for the sale of natural ingredients to the cosmetics sector. We are reiterating both our Buy rating and TP of €24.6.

## Research partially paid for by the Issuer

### Key data

Price (€)	12.5
Industry	Healthcare
Ticker	ALPAT-FR
Shares Out (m)	1.091
Market Cap (m €)	13.6
Next event	RN 2022 : avril 2023

### Ownership (%)

Famille Fèvre	28.4
Famille Bourgaud	6.3
Clariant	10.1
Vetoquinol	2.1
Free float	52.1

EPS (€)	12/23e	12/24e	12/25e
Estimates	0.13	1.08	1.74
Change vs previous estimates (%)	0.00	0.00	0.00

Performance (%)	1D	1M	YTD
Price Perf	0.0	-5.3	-6.0
Rel CAC Mid&Small	-0.0	-0.4	-11.7



TP ICAP Midcap Estimates	12/22	12/23e	12/24e	12/25e	Valuation Ratio	12/23e	12/24e	12/25e
Sales (m €)	2.3	3.0	5.0	7.0	EV/Sales	6.1	3.6	2.4
Current Op Inc (m €)	-3.0	-2.5	-1.7	-0.9	EV/EBITDA	na	15.9	9.0
Current op. Margin (%)	na	na	na	na	PE	94.8	11.6	7.2
EPS (€)	-0.73	0.13	1.08	1.74				
DPS (€)	0.00	0.00	0.00	0.00				
Yield (%)	0.0	0.0	0.0	0.0				
FCF (m €)	-0.9	-0.1	0.3	1.1				

Analyst

Claire Deray - Sponsor Finance for TPICAP Midcap

## FINANCIAL DATA

<b>Income Statement</b>	<b>12/20</b>	<b>12/21</b>	<b>12/22</b>	<b>12/23e</b>	<b>12/24e</b>	<b>12/25e</b>
Sales	1.3	2.3	2.3	3.0	5.0	7.0
Changes (%)	7.1	83.4	1.3	28.5	66.7	40.0
Gross profit	1.4	2.9	2.9	3.7	6.1	8.4
% of Sales	112.7	127.0	125.7	123.3	121.0	120.0
<b>EBITDA</b>	<b>-1.2</b>	<b>-0.9</b>	<b>-0.8</b>	<b>0.0</b>	<b>1.1</b>	<b>1.9</b>
% of Sales	-99.5	-39.6	-35.5	0.3	22.5	26.6
<b>Current operating profit</b>	<b>-1.6</b>	<b>-2.8</b>	<b>-3.0</b>	<b>-2.5</b>	<b>-1.7</b>	<b>-0.9</b>
% of Sales	-127.1	-123.2	-129.7	-83.0	-33.5	-13.4
Non-recurring items	0.0	1.2	1.3	1.6	1.8	1.8
EBIT	-1.6	-2.1	-1.7	-0.9	0.1	0.9
Net financial result	-0.1	-0.1	-0.2	-0.1	-0.1	-0.1
Income Tax	0.8	1.1	1.1	1.2	1.2	1.2
Tax rate (%)	55.2	48.7	58.1	116.8	-3,314.9	-152.9
<b>Net profit, group share</b>	<b>-0.7</b>	<b>-1.1</b>	<b>-0.8</b>	<b>0.1</b>	<b>1.2</b>	<b>2.0</b>
EPS	na	na	na	0.13	1.08	1.74
<b>Financial Statement</b>	<b>12/20</b>	<b>12/21</b>	<b>12/22</b>	<b>12/23e</b>	<b>12/24e</b>	<b>12/25e</b>
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Tangible and intangible assets	4.4	9.4	9.6	9.8	9.8	9.8
Financial assets	5.2	0.1	0.1	0.1	0.1	0.1
Working capital	1.9	2.1	2.0	2.1	3.0	3.9
Other Assets	2.0	0.0	0.0	0.0	0.0	0.0
Shareholders equity group	9.5	7.7	6.9	7.0	8.2	10.2
Minorities	0.0	0.2	0.0	0.0	0.0	0.0
LT & ST provisions and others	0.0	0.1	0.3	0.4	0.4	0.5
Net debt	4.0	3.7	4.6	4.6	4.3	3.1
Other liabilities	7.0	12.0	13.0	14.0	15.0	16.0
<b>Liabilities</b>	<b>13.6</b>	<b>11.6</b>	<b>11.8</b>	<b>12.0</b>	<b>13.0</b>	<b>13.9</b>
Net debt excl. IFRS 16	4.0	3.7	4.6	4.6	4.3	3.1
Gearing net	0.4	0.5	0.7	0.7	0.5	0.3
Leverage	-3.2	-4.0	-5.5	461.3	3.8	1.7
<b>Cash flow statement</b>	<b>12/20</b>	<b>12/21</b>	<b>12/22</b>	<b>12/23e</b>	<b>12/24e</b>	<b>12/25e</b>
ΔWCR	-0.2	-0.6	0.1	-0.1	-0.9	-0.9
Net capex	-0.6	-1.2	-1.2	-1.1	-1.0	-1.1
FCF	-1.3	-1.6	-0.9	-0.1	0.3	1.1
Acquisitions/Disposals of subsidiaries	-1.6	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.4	0.0	0.0	0.0	0.0
Change in borrowings	1.5	0.4	0.0	-0.5	-0.5	-0.5
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of leasing debt	0.0	0.0	0.0	0.0	0.0	0.0
Equity Transaction	0.0	-0.0	0.0	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0
Change in net cash over the year	-1.3	-0.8	-0.9	-0.5	-0.2	0.6
ROA (%)	na	na	na	1.4%	9.3%	12.0%
ROE (%)	na	na	na	2.5%	15.0%	19.5%
ROCE (%)	na	na	na	3.5%	na	na

## DISCLAIMER

### Analyst certifications

This research report (the “Report”) has been approved by Midcap, a business division of TP ICAP (Europe) SA (“Midcap”), an Investment Services Provider authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (“ACPR”). By issuing this Report, each Midcap analyst and associate whose name appears within this Report hereby certifies that (i) the recommendations and opinions expressed in the Report accurately reflect the research analyst’s and associate’s personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst’s or associate’s compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst or associate in the Report.

### Methodology

This Report may mention evaluation methods defined as follows:

1. DCF method: discounting of future cash flows generated by the company's operations. Cash flows are determined by the analyst's financial forecasts and models. The discount rate used corresponds to the weighted average cost of capital, which is defined as the weighted average cost of the company's debt and the theoretical cost of its equity as estimated by the analyst.
2. Comparable method: application of market valuation multiples or those observed in recent transactions. These multiples can be used as references and applied to the company's financial aggregates to deduce its valuation. The sample is selected by the analyst based on the characteristics of the company (size, growth, profitability, etc.). The analyst may also apply a premium/discount depending on his perception of the company's characteristics.
3. Assets and liabilities method: estimate of the value of equity capital based on revalued assets adjusted for the value of the debt.
4. Discounted dividend method: discounting of estimated future dividend flows. The discount rate used is generally the cost of capital.
5. Sum of the parts: this method consists of estimating the various activities of a company using the most appropriate valuation method for each of them, then realizing the sum of the parts.


### Conflict of Interests between TP ICAP Midcap and the Issuer

D. Midcap or any related legal entity is a market maker or liquidity provider with whom a liquidity agreement has been entered into in respect of the Issuer's financial instruments: PAT

F. Midcap or any legal entity related to it is party to any other agreement with the Issuer relating to the provision of investment services in connection with the corporate activity: PAT

G. Midcap and the Issuer have agreed to the provision by the former to the latter of a service for the production and distribution of the investment recommendation on the said Issuer: PAT

### History of investment rating and target price – PAT



## Distribution of Investment Ratings

Rating	Recommendation Universe*	Portion of these provided with investment banking services**
Buy	83%	64%
Hold	14%	38%
Sell	1%	50%
Under review	1%	0%

Midcap employs a rating system based on the following:

Buy: Expected to outperform the markets by 10% or more over a 6 to 12 months horizon.

Hold: expected performance between -10% and +10% compared to the market over a 6 to 12 months horizon.

Sell: Stock is expected underperform the markets by 10% or more over a 6 to 12 months horizon.

The history of ratings and target prices for the Issuers covered in this report are available on request at <https://researchtpicap.midcapp.com/en/disclaimer>.

## General Disclaimer

This Report is confidential and is for the benefit and internal use of the selected recipients only. No part of it may be reproduced, distributed, or transmitted without the prior written consent of Midcap

This Report is published for information purposes only and does not constitute a solicitation or an offer to buy or sell any of the securities mentioned herein. The information contained in this Report has been obtained from sources believed to be reliable and public, Midcap makes no representation as to its accuracy or completeness. The reference prices used in this Report are closing prices of the day before the publication unless otherwise stated. All opinions expressed in this Report reflect our judgement at the date of the documents and are subject to change without notice. The securities discussed in this Report may not be suitable for all investors and are not intended to recommend specific securities, financial instruments, or strategies to particular clients. Investors should make their own investment decisions based on their financial situation and investment objectives. The value of the income from your investment may vary due to changes in interest rates, changes in the financial and operating conditions of companies and other factors. Investors should be aware that the market price of the securities discussed in this Report may be volatile. Due to the risk and volatility of the industry, the company, and the market in general, at the current price of the securities, our investment rating may not correspond to the stated price target. Additional information regarding the securities mentioned in this Report is available on request.

This Report is not intended for distribution or use by any entity who is a citizen or resident of, or an entity located in any locality, territory, state, country, or other jurisdiction where such distribution, publication, availability, or use would be contrary to or limited by law or regulation. Entity or entities in possession of this Report must inform themselves about and comply with any such restrictions, including MIFID II. This Report is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of MIFID II regulation. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. The Report is subject to restricted circulation. The research was conducted in accordance with the provisions of the Charter. Midcap has adopted effective administrative and organizational arrangements, including "information barriers", to prevent and avoid conflicts of interest regarding investment recommendations. The remuneration of financial analysts who participate in the preparation of the recommendation is not linked to the corporate finance activity.